Skip to main content

Table 2.

Metabolic parameters at baseline (T0), 8 weeks (T1), and 16 weeks (T2) of the study in the experimental group and in the control group.

Mean ± s.d. ANOVA P-value GLM P-value
Group T0 (baseline) T1 (8 weeks) T2 (16 weeks) T0 vs T1 T1 vs T2 T0 vs T2 Time Time × treatment
Glucose, fasting (mg/dL) Experimental 82.2 ± 6.7 81.4 ± 7.5 84.9 ± 7.9 1.00000 1.00000 1.00000 0.53591 0.98798
Control 88.0 ± 16.9 85.2 ± 11.5 88.6 ± 14.2 1.00000 0.67136 1.00000 0.56461
Insulin, fasting (μU/mL) Experimental 13.4 ± 7.0 8.6 ± 3.9 9.9 ± 5.6 0.03898 0.98329 0.08481 0.01294 0.95010
Control 17.6 ± 9.9 12.9 ± 5.5 15.2 ± 8.4 0.12356 0.89186 1.00000 0.14258
HOMA-IR index Experimental 2.74 ± 1.48 1.75 ± 0.89 2.11 ± 1.26 0.06118 1.00000 0.15121 0.02379 0.81895
Control 3.96 ± 2.73 2.79 ± 1.48 3.43 ± 2.28 0.15988 0.53596 1.00000 0.15080
Total cholesterol (mg/dL) Experimental 194 ± 34 165 ± 26 174 ± 32 0.00433 0.64525 0.03723 0.00056 0.14060a
Control 195 ± 41 190 ± 41 188 ± 39 1.00000 1.00000 1.00000 0.86452a
HDL cholesterol (mg/dL) Experimental 51.8 ± 7.3 44.8 ± 6.4 49.4 ± 6.4 0.04802 0.06807 0.88822 0.01721 0.34995
Control 49.1 ± 7.7 45.4 ± 7.1 48.3 ± 11.2 0.36801 0.55491 1.00000 0.31895
Triglycerides (mg/dL) Experimental 126 ± 79 84 ± 19 78 ± 23 0.39306 1.00000 0.15047 0.07991a 0.58854
Control 123 ± 69 111 ± 62 102 ± 57 0.22285 1.00000 0.34885 0.15210
LDL cholesterol (mg/dL) Experimental 117 ± 25 103 ± 25 109 ± 29 0.16966 0.66260 0.93629 0.11683 0.25302
Control 122 ± 31 123 ± 34 123 ± 32 1.00000 1.00000 1.00000 0.98158
AST (IU/L) Experimental 24.9 ± 9.7 22.7 ± 8.4 18.0 ± 4.7 1.00000 0.30839 0.09454 0.05266 0.42454
Control 26.0 ± 13.0 24.6 ± 13.9 24.1 ± 11.3 1.00000 1.00000 0.93344 0.53769
ALT (IU/L) Experimental 36.7 ± 35.3 28.1 ± 27.2 20.9 ± 12.9 0.56761 1.00000 0.51606 0.20348 0.75997
Control 37.6 ± 36.8 32.3 ± 38.9 29.9 ± 31.4 1.00000 1.00000 0.42616 0.32149

aP-values of variables violating the sphericity assumption were adjusted using the Huynh–Feldt correction.

ALT, alanine aminotransferase; ANOVA, analysis of variance; AST, aspartate aminotransferase; GLM, general linear model, HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; LDL, low-density lipoprotein.